|
|
降糖降脂药物研究进展
|
Abstract:
| [1] | 朱芳莹, 董正伟, 朱文渊, 柳志强. 糖尿病治疗药物及其合成进展[J]. 发酵科技通讯, 2016, 45(3): 175-181. |
| [2] | 晏黎, 田静. 降糖药物的研究进展[J]. 中国医药导报, 2008, 5(2): 22-23. |
| [3] | 胡文祥, 等. 一种降糖及降脂药物组合物及其制备方法[P]. 中国发明专利, ZL200710179390.3. |
| [4] | 韩谢, 邵开元, 胡文祥. 小檗碱结构修饰的研究进展[J]. 武汉工程大学学报, 2018, 40(1): 1-7. |
| [5] | 韩谢, 邵开元, 胡文祥. 微波辐射合成9-氧-2-溴乙基小檗碱工艺研究[J]. 微波化学, 2017, 1(1): 8-14. |
| [6] | Xie, H., Shao, K.Y. and Hu, W.X. (2018) Synthesis of 9-Substituted Berberine Derivatives with Microwave Irradiation. Chemical Research in Chinese Universities, 1, 1-7. |
| [7] | Hamid, A., Yusoff, M.M., Liu, M., et al. (2015) α-Glucosidase and α-Amylase Inhibitory Constituents of Tinospora crispa: Isolation and Chemical Profile Confirmation by Ultra-High Performance Liquid Chromatography-Quadrupole Time-of- Flight/Mass Spectrometry. Journal of Functional Foods, 16, 74-80. https://doi.org/10.1016/j.jff.2015.04.011 |
| [8] | Zhang, J., Tang, H., Deng, R., et al. (2015) Berberine Suppresses Adipocyte Differentiation via Decreasing CREB Transcriptional Activity. Plos One, 10, e0125667. https://doi.org/10.1371/journal.pone.0125667 |
| [9] | Choi, Y.J., Lee, K.Y., Jung, S.H., et al. (2017) Activation of AMPK by Berberine Induces Hepatic Lipid Accumulation by Upregulation of Fatty Acid Translocase CD36 in Mice. Toxicology & Applied Pharmacology, 316, 74-82.
https://doi.org/10.1016/j.taap.2016.12.019 |
| [10] | Sun, Y., Xia, M., Yan, H., et al. (2018) Berberine Attenuates He-patic Steatosis and Enhances Energy Expenditure in Mice by Inducing Autophagy and Fibroblast Growth Factor 21. British Journal of Pharmacology, 175, 374-387.
https://doi.org/10.1111/bph.14079 |
| [11] | Kietzmann, T. and Ganjam, G.K. (2005) Glucokinase: Old Enzyme, New Target. Expert Opinion on Therapeutic Patents, 6, 705-713. https://doi.org/10.1517/13543776.15.6.705 |
| [12] | 郑宏庭, 邓华聪. 葡萄糖激酶与糖尿病的研究进展[J]. 中国临床康复, 2004, 8(27): 5960-5961. |
| [13] | 黄卉, 申竹芳. 以葡萄糖激酶为靶点的抗糖尿病新药研究[J]. 中国药理学通报, 2006, 22(9): 1025-1029. |
| [14] | 刘永贵, 解学星, 吴疆, 沈雪砚, 陈常青. 治疗2型糖尿病的新靶点药物研究进展[J]. 现代药物与临床, 2015, 30(2): 222-227. |
| [15] | Du, X.H.H., Xiong, R.J., Dransfield, Y., Park, P., Kohn, J., Pattaropong, T.J., Lai, V., Fu, S.J., Jiao, Z., Chow, X.Y., Jin, D., Davda, L., Veniant, J., Anderson, M.M., Baer, D.A., Bencsik, B.R., Boyd, J.R., Chicarelli, S.A., Mohr, M.J., Wang, P.J., Condroski, B., De Wolf, K.R., Conn, W.E., Yang, M.T.T., Aicher, J., Medina, T.D., Coward, J.C., Houze, P. and Jonathan, B. (2014) C5-Alkyl-2-Methylurea-Substituted Pyridines as a New Class of Glucokinase Activators. ACS Medicinal Chemistry Letters, 12, 1284-1289. https://doi.org/10.1021/ml500341w |
| [16] | Lee, P.K., Hyun, B.M., Han, K.H., Lee, T., Choi, D.H. and Ho, H. (2015) Design and Synthesis of Acetylenyl Benzamide Derivatives as Novel Glucokinase Activators for the Treatment of T2DM. ACS Medicinal Chemistry Letters, 3, 296-301. https://doi.org/10.1021/ml5004712 |
| [17] | 孟梅. 胰高血糖素与2型糖尿病[J]. 国际病理科学与临床杂志, 2013, 33(2): 160-164. |
| [18] | 李柯, 吴霞, 邵加庆. 基于胰高血糖素的糖尿病治疗药物研究进展[J]. 国际内分泌代谢杂志, 2018, 38(1): 15-18. |
| [19] | Young, A. (2005) Inhibition of Glucagon Secretion. Advances in Pharmacology, 52, 151-171.
https://doi.org/10.1016/S1054-3589(05)52008-8 |
| [20] | Lin, S., et al. (2015) A Novel Series of Inda-zole-/Indole-Based Glucagon Receptor Antagonists. Bioorganic and Medicinal Chemistry Letters, 19, 4143-4147. https://doi.org/10.1016/j.bmcl.2015.08.015 |
| [21] | Hasegawa, F., et al. (2014) Discovery of Fu-ran-2-Carbohydrazides as Orally Active Glucagon Receptor Antagonists. Bioorganic and Medicinal Chemistry Letters, 17, 4266-4270. https://doi.org/10.1016/j.bmcl.2014.07.025 |
| [22] | De Mong, D., Dai, X., Hwa, J., Miller, M., Lin, S.-I., Kang, L., Stamford, A., Greenlee, W., Yu, W., Wong, M., Lavey, B., Kozlowski, J., Zhou, G., Yang, D.-Y., Patel, B., Soriano, A., Zhai, Y., Sondey, C., Zhang, H., Lachowicz, J., Grotz, D., Cox, K., Morrison, R., Andreani, T. and Cao, Y. (2014) The Discovery of N-((2H-Tetrazol-5-yl)methyl)-4-((R)- 1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): A Potent and Selective Glucagon Receptor Antagonist. Journal of Medicinal Chemistry, 6, 2601-2610.
https://doi.org/10.1021/jm401858f |
| [23] | 刘浩淼, 胡晓雯, 周金培, 张惠斌. G蛋白偶联受体119激动剂及其构效关系的研究进展[J]. 中国药科大学学报, 2013, 44(1): 11-19. |
| [24] | Ohishi, T. and Yoshida, S. (2012) The Thera-peutic Potential of GPR119 Agonists for Type 2 Diabetes. Expert Opinion on Investigational Drugs, 3, 321-328. https://doi.org/10.1517/13543784.2012.657797 |
| [25] | Shigeru, Y. (2011) GPR119 Agonist for the Treatment of Type 2 Diabetes. 第一届内分泌与代谢大会论文集, 169. |
| [26] | 姜思屹, 于萍, 李强. G蛋白偶联受体119激动剂在2型糖尿病治疗中的应用[J]. 中国医药, 2015, 10(10): 1566-1568. |
| [27] | Gillespie, P., Goodnow Jr., R.A., Saha, G., Bose, G., Moulik, K., Zwingelstein, C., Myers, M., Conde-Knape, K., Pietranico-Cole, et al. (2014) Discovery of py-razolo[3,4-d]pyrimidine Derivatives as GPR119 Agonists. Bioorganic and Medicinal Chemistry Letters, 3, 949-953. https://doi.org/10.1016/j.bmcl.2013.12.063 |
| [28] | Jeon, M.-K., Lee, K.M., Kim, I.H., Jang, Y.K., Kang, S.K., Lee, J.M., Jung, K.-Y., Kumar, J.A., Rhee, S.D., Jung, W.H., Song, J.S., Bae, M.A., Kim, K.R. and Ahn, J.H. (2014) Syn-thesis and Biological Evaluation of Thienopyrimidine Derivatives as GPR119 Agonists. Bioorganic and Medicinal Chemistry Letters, 17, 4281-4285.
https://doi.org/10.1016/j.bmcl.2014.07.020 |
| [29] | Wang, Y., Yu, M., Zhu, J., Zhang, J., Kayser, F., Medina, J.C., Siegler, K., Conn, M., Shan, B., Grillo, M.P., Liu, J. and Coward, P. (2014) Discovery and Optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridine 4-yl)-1,2,4-oxadiazoles as Novel GPR119 Ago-nists. Bioorganic and Medicinal Chemistry Letters, 4, 1133-1137.
https://doi.org/10.1016/j.bmcl.2013.12.127 |
| [30] | Yu, M., Zhang, J., Wang, Y., Zhu, J., Kayser, F., Medina, J.C., Siegler, K., Conn, M., Shan, B., Grillo, M.P., Coward, P. and Liu, J. (2014) Discovery and Optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c] pyridin-4-yloxy) phenyl) Benzenesulfonamides as Novel GPR119 Agonists. Bioorganic and Medicinal Chemistry Letters, 1, 156-160.
https://doi.org/10.1016/j.bmcl.2013.11.053 |
| [31] | Buzard, D.J., Kim, S.H., Lehmann, J., Han, S., Calderon, I., Wong, A., Kawasaki, A., Narayanan, S., Bhat, R., Gharbaoui, T., Lopez, L., Yue, D., Whelan, K., Al-Shamma, H., Unett, D.J., Shu, H.H., Tung, S.F., Chang, S., Chuang, C.F., Morgan, M., Sadeque, A., Chu, Z.L., Leonard, J.N. and Jones, R.M. (2014) Discovery and Optimization of 5-fluoro- 4,6-dialkoxypyrimidine GPR119 Agonists. Bioorganic and Medicinal Chemistry Letters, 17, 4332-4335.
https://doi.org/10.1016/j.bmcl.2014.06.071 |
| [32] | 俞牧雨, 殷峻. 腺苷酸活化蛋白激酶调节糖脂代谢的研究进展[J]. 山东医药, 2017, 57(1): 109-111. |
| [33] | Zhang, B.B., Zhou, G. and Li, C. (2009) AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome. Cell Metabolism, 9, 407-416. https://doi.org/10.1016/j.cmet.2009.03.012 |
| [34] | Hardie, D.G. (2008) AMPK: A Key Regulator of Energy Balance in the Single Cell and the Whole Organism. International Journal of Obesity, 32, S7-S12. https://doi.org/10.1038/ijo.2008.116 |
| [35] | 胡淑国. 腺苷酸活化蛋白激酶与胰岛素抵抗[J]. 国际内科学杂志, 2009, 36(3): 137-140. |
| [36] | 王淼, 邹大进. 蛋白酪氨酸磷酸酶-1B与2型糖尿病[J]. 国际内分泌代谢杂志, 2006, 26(6): 388-390. |
| [37] | 丁玉静, 刘德敏. 蛋白酪氨酸磷酸酶-1B及其抑制剂与2型糖尿病[J]. 国际内分泌代谢杂志, 2006, 26(s): 6-8. |
| [38] | Yip, S.-C., Saha, S. and Chernoff, J. (2010) PTP1B: A Double Agent in Metabolism and Onco-genesis. Trends in Biochemical Sciences, 35, 442-449. https://doi.org/10.1016/j.tibs.2010.03.004 |
| [39] | Xie, C., Sun, Y., Pan, C.Y., Tang, L.M. and Guan, L.P. (2014) 2,4-Dihydroxy-chalcone Derivatives as Novel Potent Cell Division Cycle 25B Phosphatase Inhibitors and Protein Tyrosine Phosphatase 1B Inhibitors. Die Pharmazie, 4, 257-262. |
| [40] | Liu, J., Deng, X., Jin, Y., Xu, B., Liu, W., et al. (2015) Design, Synthesis, and Biological Evaluation of 2-Substituted Ethenesulfonic Acid Ester Derivatives as Selective PTP1B Inhibitors. Die Pharmazie, 7, 446-451. |
| [41] | 张晶晶, 蔡金艳, 郭姣. 11β-羟基类固醇脱氢酶1在2型糖尿病中的研究进展[J]. 食品与药品, 2017, 19(2): 142-146. |
| [42] | Webster, S.P. and Pallin, T.D. (2007) 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors as Thera-peutic Agents. Expert Opinion on Therapeutic Patents, 12, 1407-1422. https://doi.org/10.1517/13543776.17.12.1407 |
| [43] | 王薪宁, 徐斌, 周金培, 张惠斌. 基于新靶点的抗糖尿病药物研究进展[J]. 中国医科大学学报, 2015, 46(2): 141-152. |
| [44] | 张莉静, 卢曦. 基于PPAR抗糖尿病药物的研究进展[J]. 国外医学药学分册, 2004, 31(5): 287-291. |
| [45] | Lu, J.X., Lei, L., Huan, Y., Li, Y.Q., Zhang, L.J., Shen, Z.F., Hu, W.X. and Feng, Z.Q. (2014) Design, Synthesis, and Activity Evaluatian of GK/PPARγ Dual-Daret-Directed Ligands as Hypoglycemic Agents. ChemMedChem, 9, 922-927.
https://doi.org/10.1002/cmdc.201400009 |
| [46] | 王海勇. 降血脂药物的研究进展[J]. 国外医学药学分册, 2004, 31(3): 160-166. |
| [47] | 李慧, 景贤, 邓晓兰, 欧阳冬生. 调脂药物的作用靶点[J]. 中南大学学报(医学版), 2013, 38(1): 101-108. |
| [48] | He, K., Kou, S., Zou, Z., et al. (2016) Hypolipidemic Effects of Alkaloids from Rhizoma Coptidis in Diet-Induced Hyperlipidemic Hamsters. Planta Medica, 82, 690-697. https://doi.org/10.1055/s-0035-1568261 |
| [49] | Thomson, D.M. and Winder, W.W. (2009) AMP-Activated Protein Kinase Control of Fat Metabolism in Skeletal Muscle. Acta Physiologica, 196, 147-154. https://doi.org/10.1111/j.1748-1716.2009.01973.x |
| [50] | Wang, C., Huang, Z., Wang, L., et al. (2014) Application of Berberine Derivative in Preparation of Drug for Treating Atherosclerosis. CN 103804374 A. |
| [51] | 张艳平, 许崇利, 刘霞, 高飞, 武蓉, 欧阳红生, 逄大新, 许崇波. 胆固醇转运蛋白NPC1L1的研究进展[J]. 中国动物检疫, 2012, 29(6): 76-79. |
| [52] | 何菊英, 唐敏, 藏雷. 羟甲基戊二酰辅酶A还原酶抑制剂抗高脂血症的研究进展[J]. 中国临床康复, 2003, 7(30): 4130-4131. |
| [53] | 李烁, 张志文, 管又飞. 胆汁酸受体FXR的研究进展[J]. 生理科学进展, 2003, 34(4): 314-318. |
| [54] | Forman, B.M., Goode, E., Chen, J., Oro, A.E., Bradley, D.J., Perlmann, T., Noonan, D.J., Burka, L.T., McMorris, T., Lamph, W.W., Evans, R.M. and Weinberger, C. (1995) Identification of a Nuclear Receptor That Is Activated by Farnesol Metabolites. Cell, 81, 687-693. https://doi.org/10.1016/0092-8674(95)90530-8 |
| [55] | Jiao, Y., Lu, Y. and Li, X.Y. (2015) Farnesoid X Receptor: A Master Regulator of Hepatic Triglyceride and Glucose Homeostasis. Acta Pharmacologica Sinica, 36, 44-50. https://doi.org/10.1038/aps.2014.116 |
| [56] | Ricketts, M.L., Boekschoten, M.V., Kreeft, A.J., Hooiveld, G.J., Moen, C.J., Müller, M., Frants, R.R., Kasanmoentalib, S., Post, S.M., Princen, H.M., Porter, J.G., Katan, M.B., Hofker, M.H. and Moore, D.D. (2007) The Cholesterol-Raising Factor from Coffee Beans, Cafestol, as an Agonist Ligand for the Farnesoid and Pregnane X Receptors. Molecular Endocrinology, 21, 1603-1616. https://doi.org/10.1210/me.2007-0133 |
| [57] | Carr, R.M. and Reid, A.E. (2015) FXR Agonists as Therapeutic Agents for Non-Alcoholic Fatty Liver Disease. Current Atherosclerosis Reports, 3, 14. https://doi.org/10.1007/s11883-015-0500-2 |
| [58] | 张芮, 陈斯钰. 脂肪酸合成酶(FAS)的研究综述[J]. 农村经济与科技, 2018, 29(13): 103-105. |
| [59] | Liang, Y., Ma, X.F., Hao, J., Hou, Y.F. and Tian, W.X. (2007) Natural Inhibitors of Fatty Acid Synthase from Fruits. Proceeding of the International Enzyme Engineering Conference, 87. |
| [60] | Tian, W., Ma, X., Zhang, S., Sun, Y. and Li, B. (2011) Fatty Acid Synthase Inhibitors from Plants and Their Potential Application in the Prevention of Metabolic Syndrome. Clinical Oncology and Cancer Research, 1, 1-9. |
| [61] | 敏霞, 巫冠中. 脂肪酸合成酶与疾病[J]. 亚太传统医药, 2012, 8(9): 210-212. |
| [62] | 王世鹏. 前蛋白转化酶枯草溶菌素9与心血管疾病关系研究进展[J]. 心血管病学进展, 2016, 37(6): 685-688. |
| [63] | Gouni-Berthold, I. and Berthold Heiner, K. (2014) PCSK9 Antibodies for the Treatment of Hypercholesterolemia. Nutrients, 12, 5517-5533. |
| [64] | Verbeek, R.S., Hovingh, R.M. and Kees, G. (2015) PCSK9 Inhibitors: Novel Therapeutic Agents for the Treatment of Hypercholesterolemia. European Journal of Pharmacology, No. A, 38-47. |
| [65] | 曾雨薇. 前蛋白转化酶枯草溶菌素9抑制剂的研究进展[J]. 心血管病学进展, 2015, 36(3): 341-345. |
| [66] | 顾觉奋, 牛佳. 角鲨烯合成酶抑制剂降血脂作用及机制的研究进展[J]. 药学进展, 2007, 31(1): 15-20. |
| [67] | 胡越, 许军, 刘燕华, 王增涛, 黄黎敏, 方加龙, 王晨. PPARα激动剂降血脂作用的研究进展[J]. 中国药科大学学报, 2016, 47(1): 118-124. |
| [68] | 崔婷婷, 邢天宇, 褚衍凯, 李辉, 王宁. PPARγ在脂肪生成中的遗传和表观遗传调控[J]. 遗传, 2017, 39(11): 1066-1077. |
| [69] | Peymani, M., Ghaedi, K., Irani, S. and Nasr-Esfahani, M.H. (2016) Peroxisome Proliferator-Activated Receptor γ Activity Is Required for Appropriate Cardiomyocyte Differentiation. Cell Journal (Yakhteh), 18, 221-228. |
| [70] | 荆丹清, 尹士男, 母义明. PPARα/γ双重激动剂研究进展[J]. 中国药物应用与监测, 2007(4): 46-49. |
| [71] | 梁瑜, 郭长彬, 张冲, 侯振更. 肝脏X受体激动剂研究进展[J]. 药学学报, 2012, 47(4): 427-433. |
| [72] | 顾文娟, 李江. 肝脏X受体研究在心血管疾病中的应用展望[J]. 医学与哲学(临床决策论坛版), 2010, 31(1): 52-54. |
| [73] | 刘接卿. 三种中药的化学成分及其活性研究[J]. 博士学位论文, 北京: 首都师范大学, 2009. |
